Cipla Limited has entered into a perpetual license agreement with Novartis Pharma AG of Switzerland to produce and sell Galvus and Galvus combination brands, which are used to treat type 2 diabetes.
The agreement will take effect from January 1, 2026, subject to certain conditions being met beforehand. In the meantime, the company said that it will continue to market and distribute Galvus-branded products.
Galvus is a leading brand in the Dipeptidyl Peptidase-4 (DPP4) sector and is widely recognized as one of the top brands in oral diabetic medication.
With reported sales of Rs 268 crore (IQVIA MAT February 2023), Galvus has the potential to make a substantial contribution to Cipla’s portfolio in the diabetes care continuum space.
The agreement is anticipated to strengthen Cipla’s position in the diabetes category in India, solidifying its standing as one of the leading players in this market segment.
At around 2.52 PM, Cipla is trading 0.90% higher at Rs 901.40, against the previous close of Rs 893.35 on NSE. The counter touched an intraday high and low of Rs 904.50 and Rs 894.20 respectively.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.